Online Education
- Home
- Online Education
Important Note
You will need to login first in order to enroll or view an activity. Login Here
*Note: ✔ = Contact Hours Provided AND ✖ = No Contact Hours Provided
A School Nurse's Guide to Bleeding Disorders: Hemophilia
- Credits: 0.75 (ANCC)
- Expiration Date: May 27, 2024
A School Nurse's Guide to Bleeding Disorders: Hemophilia Details
Activity Number and Title
22HT00053 A School Nurses Guide to Bleeding Disorders: Hemophilia
Release Date
May 27, 2022
Expiration Date
5:00 PM Eastern, May 27, 2024
The estimated time to complete this activity is 45 minutes.
Purpose Statement
This online learning activity aims to enable the learner to develop basic knowledge and skills regarding etiology, inheritance, severity, and treatment of hemophilia, recognition of hemophilia symptoms, and use of strategies to promote a safe and positive learning environment.
Activity Description
The activity is designed for school nurses, nurse practitioners, and other school personnel who require basic knowledge and skill to effectively practice and teach in schools attended by a student with hemophilia. This involves debunking common myths that persist about hemophilia and replacing those myths with factual information concerning the etiology, inheritance, severity, and treatment of hemophilia. It includes information on identifying prevalent locations and symptoms of bleeding in hemophilia. Finally, the activity reviews strategies that may be implemented in the school setting to promote a safe and positive learning environment for the student with hemophilia.
Target Audience
This accredited continuing education activity is designed for nurses and nurse practitioners who practice in schools attended by a student with hemophilia. It may also be helpful to teachers, physical education and sports coaches, administrators, guidance counselors, and other educators and healthcare professionals needing an introduction to school related considerations in hemophilia.
Educational Objectives
At the conclusion of this activity, the participants should be better able to:
- Dispel common misconceptions about hemophilia
- Review basic information about the etiology, inheritance, and severity of hemophilia
- Identify prevalent locations and symptoms of joint and muscle bleeding in hemophilia
- Describe hemophilia treatment strategies and medications utilized and avoided in hemophilia management
- Discuss guidelines for participation in physical activity and sports by persons with hemophilia
- Integrate reasonable accommodations in the school setting to promote a safe and positive learning environment for the student with hemophilia
- Explain the role of the Hemophilia Treatment Center as a resource for support for schools attended by a student with hemophilia
Faculty
- Lisa Bowman, RN, BSN, ASN
- Molly Simmons, RN, BSN
Requirements for Successful Completion
In order to receive continuing education credits, you must complete these steps prior to the activity expiration date.
- Read the Disclosure Information found in the To Dos section.
- Complete the learning activity
- Complete the evaluation
- Complete the post-test with a score of 70% or better
- Upon successful completion of the post-test your certificate of completion will be available to print or save
Accreditation Statement and Contact Hours
In support of improving patient care, this activity has been planned and implemented by University of Nebraska Medical Center and Partners in Bleeding Disorders Education Program. University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
NURSES/NURSE PRACTITIONERS
The University of Nebraska Medical Center designates this activity for 0.75 ANCC contact hours. Nurses should only claim credit for the actual time spent participating in the activity.
Financial Support
Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.
Contact Information
If you have any questions about this activity, please contact Brooke Hernandez in Indianapolis, IN, 317-871-0011 ext. 813 or via email at bhernandez@ihtc.org. For technical support please email support@partnersprn.org or open a ticket in the Partners Support Center.
System Requirements
- 2 gigabytes of RAM
- High-speed internet connection
- Internet browser (current version) Firefox, Safari, Chrome, or Explorer
- Cookies and JavaScript must be enabled in the browser
A School Nurse's Guide to Bleeding Disorders: von Willebrand Disease
- Credits: 0.5 (ANCC)
- Expiration Date: December 23, 2023
A School Nurse's Guide to Bleeding Disorders: von Willebrand Disease Details
Activity Number and Title
22HT00081 A School Nurses Guide to Bleeding Disorders: von Willebrand Disease
Release Date
December 22, 2022
Expiration Date
5:00 PM Eastern, December 23, 2023
The estimated time to complete this activity is 30 minutes.
Purpose Statement
This activity aims to enable the learner to enhance his/her knowledge about von Willebrand disease (VWD), common treatment methods/products, and accommodations recommended to provide a safe and positive learning environment for the student with VWD.
Activity Description
A School Nurse's Guide to Bleeding Disorders: von Willebrand Disease contains information about von Willebrand disease (VWD), its treatment, and accommodations that must be made in order to promote a safe and positive learning environment for the student with VWD. This includes a definition of VWD and a description of common symptoms; description of VWD treatment; and exploration of the Hemophilia Treatment Center (HTC) comprehensive care team as an essential resource in managing the student with VWD.
Target Audience
This accredited continuing education activity is designed for professional school nurses in schools attended by a child with von Willebrand disease (VWD). Teachers, physical education instructors, school administrators, and guidance counselors. Other educators and healthcare professionals who require an introduction to school-related considerations for students with VWD.
Educational Objectives
At the conclusion of this activity, the participants should be better able to:
- Apply basic information related to the etiology and symptoms of von Willebrand disease (VWD) to clinical practice with students
- Recognize common treatments utilized for VWD within the school setting
- Integrate strategies in the school setting to promote a safe and positive learning environment
Faculty
- Lisa Bowman, RN, BSN, ASN
- Molly Simmons, RN, BSN
Requirements for Successful Completion
In order to receive continuing education credits, you must complete these steps prior to the activity expiration date.
- Read the Disclosure Information found in the To Dos section.
- Complete the learning activity
- Complete the evaluation
- Complete the post-test with a score of 70% or better
- Upon successful completion of the post-test your certificate of completion will be available to print or save
Accreditation Statement and Contact Hours
In support of improving patient care, this activity has been planned and implemented by University of Nebraska Medical Center and Partners in Bleeding Disorders Education Program. University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
NURSES/NURSE PRACTITIONERS
The University of Nebraska Medical Center designates this activity for 0.5 ANCC contact hours. Nurses should only claim credit for the actual time spent participating in the activity.
Financial Support
Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.
Contact Information
If you have any questions about this activity, please contact Brooke Hernandez in Indianapolis, IN, 317-871-0011 ext. 813 or via email at bhernandez@ihtc.org. For technical support please email support@partnersprn.org or open a ticket in the Partners Support Center.
System Requirements
- 2 gigabytes of RAM
- High-speed internet connection
- Internet browser (current version) Firefox, Safari, Chrome, or Explorer
- Cookies and JavaScript must be enabled in the browser
Gene Therapy for Providers 101
- Credits: 0.75 (ACCME), 0.75 (ANCC), 0.75 (ACPE)
- Expiration Date: October 13, 2023
Gene Therapy for Providers 101 Details
Activity Number and Title
22HT57252 - Gene Therapy for Providers 101
Release Date
October 14, 2022
Expiration Date
5:00 PM Eastern, October 13, 2023
The estimated time to complete this enduring material is 45 minutes.
Purpose Statement
The purpose of this activity is to enable learners to develop basic knowledge of gene therapy for hemophilia, thereby enhancing learner competence to discuss gene therapy with patients who may benefit from this emerging treatment.
Activity Description
This learning activity provides basic education on hemophilia gene therapy, including the aims of gene therapy; the packaging, delivery, and activity of the replacement genes; and the means by which the replacement genes lead to production and/or availability of normal clotting factor in persons with hemophilia. The module will also review information that may be particularly important when discussing hemophilia gene therapy with patients, such as knowledgeable informed consent, outcomes data, and potential risks and benefits.
Target Audience
This accredited continuing education activity is designed for multidisciplinary providers at hemophilia treatment centers, including nurses, physicians, pharmacists, physical therapists, social workers, and genetic counselors providing care to persons with hemophilia A and hemophilia B.
Educational Objectives
At the conclusion of this activity, the participants should be better able to:
- Describe a pathway to preparedness for gene therapy from education of the multidisciplinary healthcare team to clinical delivery
- Provide an overview of the goal of gene therapy for hemophilia
- Explain the elements of gene therapy (i.e. packaging, administration, mechanism of action)
- Define the profile of gene therapy candidates with FVIII deficiency and FIX deficiency
- Review known adverse effects from completed and ongoing clinical trials
- Articulate critical considerations for the multidisciplinary healthcare team in providing care for patients receiving gene therapy
- Discuss issues related to obtaining knowledgeable informed consent and counseling patients
Faculty
- Steven W. Pipe, MD
- Shelley Crary, MD, MSCS
Requirements for Successful Completion
In order to receive continuing education credits, you must complete these steps prior to the activity expiration date.
- Read the Disclosure Information found in the To Dos section.
- Complete the learning activity
- Complete the evaluation
- Complete the post-test with a score of 70% or better
- Upon successful completion of the post-test your certificate of completion will be available to print or save
Accreditation Statement and Contact Hours
In support of improving patient care, this activity has been planned and implemented by University of Nebraska Medical Center and Indiana Hemophilia & Thrombosis Center. University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIANS/PHYSICIAN ASSISTANTS
The University of Nebraska Medical Center designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
PHARMACISTS (PharmDs/RPhs)
The University of Nebraska Medical Center designates this activity for 0.75 ACPE contact hours. Pharmacists should claim only the credit commensurate with the extent of their participation in the activity. Credit will be provided to NABP CPE Monitor within 60 days after the activity completion. UAN # JA0000319-9999-22-018-H01-P
NURSES/NURSE PRACTITIONERS
The University of Nebraska Medical Center designates this activity for 0.75 ANCC contact hours. Nurses should only claim credit for the actual time spent participating in the activity.
Financial Support
No commercial support was received for this activity.
Contact Information
If you have any questions about this activity, please contact Brooke Hernandez in Indianapolis, IN, 317-871-0011 ext. 813 or via email at bhernandez@ihtc.org. For technical support please email support@partnersprn.org or open a ticket in the Partners Support Center.
System Requirements
- 2 gigabytes of RAM
- High-speed internet connection
- Internet browser (current version) Firefox, Safari, Chrome, or Explorer
- Cookies and JavaScript must be enabled in the browser
Gene Therapy for Providers 201
- Credits: 1 (ACCME), 1.0 (ANCC), 1.0 (ACPE)
- Expiration Date: October 13, 2023
Gene Therapy for Providers 201 Details
Activity Number and Title
22HT57253 - Gene Therapy for Providers 201
Release Date
October 14, 2022
Expiration Date
5:00 PM Eastern, October 13, 2023
The estimated time to complete this activity is 60 minutes.
Purpose Statement
The purpose of this activity is to enable HTC multidisciplinary staff and institutional stakeholders to gain knowledge on the steps necessary to prepare an institution to administer AAV-mediated gene therapy for hemophilia.
Activity Description
This learning activity is a process-oriented intermediate course that will guide HTC staff through the steps an institution must take to prepare to administer hemophilia gene therapy upon commercial availability of these products.
Target Audience
This accredited continuing education activity is designed for HTC multidisciplinary staff (physicians, physician assistants, nurses, nurse practitioners, physical therapists, social workers, pharmacists, geneticists, genetic counselors, infusion room staff) and institutional stakeholders (e.g., HTC administrators and directors, clinic and pharmacy billing staff, insurance coordinators).
Educational Objectives
At the conclusion of this activity, the participants should be better able to:
- Identify patients who are eligible for AAV-mediated gene therapy
- Discuss key concepts involving education and shared decision-making for gene therapy
- Identify logistical/infrastructure requirements to procure, reconstitute and administer gene therapy at a dosing site
- Articulate the regional approach of preparing for gene therapy administration
- Distinguish the roles and responsibilities within the HTC team involved in the safety and efficacy assessments during short-and long-term monitoring before and after gene therapy
- Describe approaches to prevention, diagnosis, and treatment of vector-induced transaminitis after gene therapy
Faculty
- Rebecca Kruse-Jarres, MD, MPH
- Ulrike Margret Reiss, MD
- Courtney Dawn Thornburg, MD, MS
Requirements for Successful Completion
In order to receive continuing education credits, you must complete these steps prior to the activity expiration date.
- Read the Disclosure Information found in the To Dos section.
- Complete the learning activity
- Complete the evaluation
- Complete the post-test with a score of 70% or better
- Upon successful completion of the post-test your certificate of completion will be available to print or save
Accreditation Statement and Contact Hours
In support of improving patient care, this activity has been planned and implemented by University of Nebraska Medical Center and Indiana Hemophilia and Thrombosis Center. University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIANS/PHYSICIAN ASSISTANTS
The University of Nebraska Medical Center designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
PHARMACISTS (PharmDs/RPhs)
The University of Nebraska Medical Center designates this activity for 1 ACPE contact hours. Pharmacists should claim only the credit commensurate with the extent of their participation in the activity. Credit will be provided to NABP CPE Monitor within 60 days after the activity completion. UAN # JA0000319-9999-22-019-H01-P
NURSES/NURSE PRACTITIONERS
The University of Nebraska Medical Center designates this activity for 1.0 ANCC contact hour. Nurses should only claim credit for the actual time spent participating in the activity.
Financial Support
No commercial support was received for this activity.
Contact Information
If you have any questions about this activity, please contact Brooke Hernandez in Indianapolis, IN, 317-871-0011 ext. 813 or via email at bhernandez@ihtc.org. For technical support please email support@partnersprn.org or open a ticket in the Partners Support Center.
System Requirements
- 2 gigabytes of RAM
- High-speed internet connection
- Internet browser (current version) Firefox, Safari, Chrome, or Explorer
- Cookies and JavaScript must be enabled in the browser
Gene Therapy for Providers 301
- Credits: 1 (ACCME), 1.0 (ANCC), 1.0 (ACPE)
- Expiration Date: October 13, 2023
Gene Therapy for Providers 301 Details
Activity Number and Title
22HT57254 Gene Therapy for Providers 301
Release Date
October 14, 2022
Expiration Date
5:00 PM Eastern, October 13, 2023
The estimated time to complete this enduring material is 60 minutes.
Purpose Statement
The purpose of this activity is to enable HTC multidisciplinary staff and hospital staff to support patients and their families as they consider hemophilia gene therapy, including education of patients and families on basic concepts in hemophilia gene therapy; administrative preparedness for providers; and short- and long-term care demands.
Activity Description
This learning activity is a process-oriented intermediate course that will guide HTC staff through the steps an institution must take to prepare to administer hemophilia gene therapy upon commercial availability of these products.
Target Audience
This accredited continuing education activity is designed for physicians, physician assistants, nurses, nurse practitioners, physical therapists, social workers, pharmacists, and infusion room staff.
Educational Objectives
At the conclusion of this activity, the participants should be better able to:
- Discuss introductory concepts in hemophilia gene therapy
- Outline the process of preparing patients, hemophilia treatment centers, and hospital systems for the administration of gene therapy
- Explain the steps necessary for multidisciplinary team members to engage in shared patient-centered and population focused problem solving when procuring a hemophilia gene therapy product, preparing the product, and infusing the patient safely
- Discuss short term monitoring, specifically immediately after infusion and during the first three months of follow up
- Discuss long term monitoring, specifically from 3 to 24 months post infusion and > 24 months post infusion
Faculty
- Doris V. Quon, MD
- Lindsey A. George, MD
Requirements for Successful Completion
In order to receive continuing education credits, you must complete these steps prior to the activity expiration date.
- Read the Disclosure Information found in the To Dos section.
- Complete the learning activity
- Complete the evaluation
- Complete the post-test with a score of 70% or better
- Upon successful completion of the post-test your certificate of completion will be available to print or save
Accreditation Statement and Contact Hours
In support of improving patient care, this activity has been planned and implemented by University of Nebraska Medical Center and Indiana Hemophilia & Thrombosis Center. University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIANS/PHYSICIAN ASSISTANTS
The University of Nebraska Medical Center designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
PHARMACISTS (PharmDs/RPhs)
The University of Nebraska Medical Center designates this activity for 1 ACPE contact hours. Pharmacists should claim only the credit commensurate with the extent of their participation in the activity. Credit will be provided to NABP CPE Monitor within 60 days after the activity completion. UAN # JA0000319-9999-22-020-H01-P
NURSES/NURSE PRACTITIONERS
The University of Nebraska Medical Center designates this activity for 1.0 ANCC contact hour. Nurses should only claim credit for the actual time spent participating in the activity.
Financial Support
No commercial support was received for this activity.
Contact Information
If you have any questions about this activity, please contact Brooke Hernandez in Indianapolis, IN, 317-871-0011 ext. 813 or via email at bhernandez@ihtc.org. For technical support please email support@partnersprn.org or open a ticket in the Partners Support Center.
System Requirements
- 2 gigabytes of RAM
- High-speed internet connection
- Internet browser (current version) Firefox, Safari, Chrome, or Explorer
- Cookies and JavaScript must be enabled in the browser
Hereditary Hemorrhagic Telangiectasia: Right Under Your Nose
- Credits: 1.0 (ACCME), 1.0 (ANCC)
- Expiration Date: May 31, 2024
Hereditary Hemorrhagic Telangiectasia: Right Under Your Nose Details
Activity Number and Title
21HT50146 Hereditary Hemorrhagic Telangiectasia: Right Under Your Nose
Release Date
June 1, 2022
Expiration Date
5:00 PM Eastern, May 31, 2024
The estimated time to complete this activity is 60 minutes.
Purpose Statement
This online learning activity aims to enable the learner to gain knowledge and expertise regarding hereditary hemorrhagic telangiectasia (HHT), including inheritance and pathophysiology, screening guidelines, management, and the importance of the multidisciplinary approach in caring for these patients.
Activity Description
This online learning activity provides a detailed introduction to hereditary hemorrhagic telangiectasia (HHT) appropriate for an audience of multidisciplinary health care providers involved in the team-based care of patients with HHT. This overview includes information on the genetic inheritance and pathophysiology of HHT as well as the widely-used Curaçao diagnostic criteria to determine if a person has HHT, consensus screening guidelines for HHT management, and an explanation of the importance of a multidisciplinary approach to care of patients with HHT. This activity incorporates case scenarios and interactive questions to encourage active learning through application of the content.
Target Audience
This accredited continuing education activity is designed for physicians, physician assistants, nurse practitioners, nurses, and other multidisciplinary team members who care for patients with hereditary hemorrhagic telangiectasia.
Educational Objectives
At the conclusion of this activity, the participants should be better able to:
- Identify the Curaçao criteria for determining the likelihood of Hereditary Hemorrhagic Telangiectasia (HHT) in an undiagnosed individual
- Describe HHT genetics and pathophysiology
- Discuss the international consensus screening guidelines for HHT management
- Review management of epistaxis, iron deficiency, and pulmonary arteriovenous malformations (PAVMs) in HHT
- Explain the importance of an HHT Center-driven multidisciplinary approach in caring for patients with HHT
Faculty
- Manjusha Kumar, MD
- Magdalena Lewandowska, MD
Requirements for Successful Completion
In order to receive continuing education credits, you must complete these steps prior to the activity expiration date.
- Read the Disclosure Information found in the To Dos section.
- Complete the learning activity
- Complete the evaluation
- Complete the post-test with a score of 70% or better
- Upon successful completion of the post-test your certificate of completion will be available to print or save
Accreditation Statement and Contact Hours
In support of improving patient care, this activity has been planned and implemented by University of Nebraska Medical Center and Indiana Hemophilia & Thrombosis Center. University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIANS/PHYSICIAN ASSISTANTS
The University of Nebraska Medical Center designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NURSES/NURSE PRACTITIONERS
The University of Nebraska Medical Center designates this activity for 1.0 ANCC contact hours. This activity is provided for 0.15 contact hours related to pharmacotherapeutic content. Nurses should only claim credit for the actual time spent participating in the activity.
Financial Support
No commercial support was received for this activity.
Contact Information
If you have any questions about this activity, please contact Brooke Hernandez in Indianapolis, IN, 317-871-0011 ext. 813 or via email at bhernandez@ihtc.org. For technical support please email support@partnersprn.org or open a ticket in the Partners Support Center.
System Requirements
- 2 gigabytes of RAM
- High-speed internet connection
- Internet browser (current version) Firefox, Safari, Chrome, or Explorer
- Cookies and JavaScript must be enabled in the browser
MASAC Pain Initiative Task Force Pain Management Guidelines for Bleeding Disorders
- Credits: 2.0 (ACCME), 2.0 (ANCC), 2 (ASWB), 0.2 (CPTA)
- Expiration Date: December 15, 2023
MASAC Pain Initiative Task Force Pain Management Guidelines for Bleeding Disorders Details
Activity Number and Title
21HT50199 - MASAC Pain Initiative Task Force Pain Management Guidelines for Bleeding Disorders
Release Date
January 10, 2022
Expiration Date
5:00 PM Eastern, December 15, 2023
The estimated time to complete this activity is 120 minutes.
The content level of this activity is intermediate.
Purpose Statement
The purpose of this enduring material is to enable the learner to gain knowledge on the opioid guidance document published in early 2020 by the Medical and Scientific Advisory Council (or MASAC).
Activity Description
In this module, there are several aspects of pain management that will be addressed. Foremost is to familiarize you with the MASAC opioid guidance document established in 2020. In addition, we will describe the importance of standardized assessment of pain. This activity will help you to determine goals for pain management and how the roles of each team member can help incorporate non-pharmacological pain management options. Lastly, opioid issues including when and how to start opioids for pain management and monitoring systems that will assist you will be covered in the modules. To enhance the learning, case studies will be examined.
Target Audience
This enduring material is intended for physicians, physician assistants, nurse practitioners, nurses, social workers, physical therapists, and other interested members of the bleeding disorder comprehensive care team.
Educational Objectives
At the conclusion of this enduring material, the participants should be better able to:
- Discuss the MASAC opioid guidance document
- Describe the importance of standardized assessment of pain in persons with bleeding disorders
- Determine realistic functional goals for pain management and how the roles of each team member can help incorporate non-pharmacological pain management options in a multimodal fashion
- Utilize appropriate state monitoring tools, as well as additional monitoring methods for evaluation of pain management progress
Faculty
- Angela Lambing, MSN, ANP, GNP
Requirements for Successful Completion
In order to receive continuing education credits, you must complete these steps prior to the activity expiration date.
- Read the Disclosure Information found in the To Dos section.
- Complete the learning activity
- Complete the evaluation
- Complete the post-test with a score of 80% or better
- Upon successful completion of the post-test your certificate of completion will be available to print or save
Accreditation Statement and Contact Hours
In support of improving patient care, this activity has been planned and implemented by University of Nebraska Medical Center and Indiana Hemophilia & Thrombosis Center. University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIANS/PHYSICIAN ASSISTANTS
The University of Nebraska Medical Center designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
NURSES/NURSE PRACTITIONERS
The University of Nebraska Medical Center designates this activity for 2.0 ANCC contact hours. Nurses should only claim credit for the actual time spent participating in the activity.
As a Jointly Accredited Organization, University of Nebraska Medical Center is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. State and provincial regulatory boards have the final authority to determine whether an individual course may be accepted for continuing education credit. University of Nebraska Medical Center maintains responsibility for this course. Social workers completing this course receive 2 continuing education credits.
PHYSICAL THERAPISTS
This activity is approved for physical therapy continuing education units (CEUs) through the California Physical Therapy Association (CPTA) (Approved for 0.2 CEUs by CPTA #22-584). While many states recognize continuing education credits from CPTA, please verify with your state Board that these credits are acceptable in your state. To learn more about CPTA, visit https://www.ccapta.org.
Financial Support
No commercial support was received for this activity. Supported by an educational grant from the National Hemophilia Foundation.
Contact Information
If you have any questions about this activity, please contact Brooke Hernandez in Indianapolis, IN, 317-871-0011 ext. 813 or via email at bhernandez@ihtc.org. For technical support please email support@partnersprn.org or open a ticket in the Partners Support Center.
System Requirements
- 2 gigabytes of RAM
- High-speed internet connection
- Internet browser (current version) Firefox, Safari, Chrome, or Explorer
- Cookies and JavaScript must be enabled in the browser
Understanding Hemophilia
- Credits: 2.0 (ANCC), 2.00 (AAPA)
- Expiration Date: February 23, 2024
Understanding Hemophilia Details
Activity Number and Title
22HT00046 Understanding Hemophilia
Release Date
February 24, 2022
Expiration Date
5:00 PM Eastern, February 23, 2024
The estimated time to complete this activity is 120 minutes.
Purpose Statement
"Understanding Hemophilia" is a 6-part online learning activity that aims to enable clinicians at U.S. Hemophilia Treatment Centers to gain knowledge and develop expertise on the pathogenesis, inheritance, symptoms, potential complications, and clinical management of hemophilia.
Activity Description
This 6-part online learning activity introduces basic concepts of hemophilia.
Part 1: Pathogenesis & Inheritance examines the coagulation system and processes, the deficit in hemophilia that interferes with clot formation, differences among types of hemophilia, and the sex-linked inheritance pattern of hemophilia.
Part 2: Symptoms & Sequelae distinguishes bleeding patterns and clinical presentation of hemophilia based on severity, differentiates types of bleeding episodes, and discusses physical/psychosocial sequelae of hemophilia.
Part 3: Factor Concentrates & Hemophilia Management discusses episodic and prophylactic management of hemophilia with clotting factor concentrate, different factor therapy protocols, and nursing considerations in administration of clotting factor concentrates.
Part 4: Introduction to Inhibitors explains the immune response and inhibitor development, signs/symptoms and risk factors of inhibitors, the impact of inhibitors on persons with hemophilia, inhibitor treatment strategies and challenges, and the positive health outcomes of immune tolerance induction therapy.
Part 5: Emicizumab covers the novel agent emicizumab, including its indications, mechanism of action, dosing options, lab considerations; as well as management of breakthrough bleeding, the boxed warning of emicizumab, use of emicizumab concurrently with bypassing agents, and potential considerations in the management of persons with hemophilia with or without inhibitors who utilize emicizumab.
Part 6: Carrier Considerations reviews hemophilia sex-linked genetics and introduces recommendations for the management of carriers and women with hemophilia, neonatal diagnosis and circumcision in males with hemophilia, and key considerations of postpartum management of carriers and women with hemophilia.
Target Audience
This enduring material is intended for nurses, nurse practitioners, physician assistants, and other clinical staff within the federally recognized U.S. Hemophilia Treatment Center (HTC) network who wish to develop an understanding of basic concepts of hemophilia. The activity is particularly appropriate for clinicians within their first six months of employment at an HTC.
Educational Objectives
At the conclusion of this enduring material, the participants should be better able to:
- Describe the pathogenesis and inheritance patterns concerning the different factor deficiencies in hemophilia including the symptoms and sequelae that may occur
- Discuss the target factor levels for situational bleeding episodes in conjunction with the appropriate factor replacement protocols, prophylactic treatments, and nursing considerations in administration of clotting factor concentrates
- Review the development and impact of inhibitors on persons with hemophilia, including signs and symptoms, risk factors, treatment implications, and nursing considerations
- Summarize the MASAC recommendations on the use of Emicizumab such as the indications, management approaches, and concurrent use with bypassing agents
- Articulate the role of genetic testing in the identification of potential carriers and women with hemophilia and the hemostatic management recommendations during pregnancy, labor and delivery, and the postpartum phases
Faculty w/ credentials
- Jennifer Maahs, MSN, PNP, RN-BC
- Amy Shapiro, MD
Requirements for Successful Completion
In order to receive continuing education credits, you must complete these steps prior to the activity expiration date
- Read the Disclosure Information found in the To Dos section.
- Complete the learning activity
- Complete the evaluation
- Complete the post-test with a score of 80% or better.
- Upon successful completion of the post-test your certificate of completion will be available to print or save
Accreditation Statement and Contact Hours
In support of improving patient care, this activity has been planned and implemented by University of Nebraska Medical Center and Partners in Bleeding Disorders Education Program. University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
NURSES/NURSE PRACTITIONERS
The University of Nebraska Medical Center designates this activity for 2.0 ANCC contact hour(s). This activity is provided for 0.3 contact hours related to pharmacotherapeutic content. Nurses should only claim credit for the actual time spent participating in the activity.
PHYSICIAN ASSISTANTS
University of Nebraska Medical Center has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 2 AAPA Category 1 CME credits. Approval is valid until February 23, 2024. PAs should only claim credit commensurate with the extent of their participation.
Financial Support
Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.
Contact Information
If you have any questions about this activity, please contact Brooke Hernandez in Indianapolis, IN, 317-871-0011 ext. 813 or via email at bhernandez@ihtc.org. For technical support please email support@partnersprn.org or open a ticket in the Partners Support Center.
System Requirements
- 2 gigabytes of RAM
- High-speed internet connection
- Internet browser (current version) Firefox, Safari, Chrome, or Explorer
- Cookies and JavaScript must be enabled in the browser
The Partners in Bleeding Disorders Education Program is supported by educational grants from Takeda Pharmaceuticals U.S.A., Inc; Genentech, a member of the Roche Group; National Bleeding Disorders Foundation (NBDF); and the Hemophilia Alliance.
Copyright © 2023 Indiana Hemophilia & Thrombosis Center. All rights reserved. Privacy Policy | Travel Policy | Terms of Service Credits